-
Mashup Score: 110Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer - 17 day(s) ago
This study of patients with early-stage triple-negative breast cancer not treated with adjuvant or neoadjuvant chemotherapy analyzes the association between tumor-infiltrating lymphocyte levels, cancer recurrence, and survival.
Source: jamanetwork.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 2TNBC Awareness Day: Unveiling New Findings and Developments - 2 month(s) ago
In an interview for Triple-Negative Breast Cancer Awareness Day, Daniel Carlson, DO, delved into the complexities of the disease, highlighting the current space and future possibilities.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet-
March 3 was Triple-Negative Breast Cancer Awareness Day & Daniel Carlson, DO, delved into the complexities of the disease in an interview. #TNBC | @AllinaHealth https://t.co/76XWHiP1zi
-
-
Mashup Score: 0Home - 3 month(s) ago
The treatment of triple-negative breast cancer (TNBC) has evolved with the emergence of newer therapies such as immunotherapy and poly(ADP-ribose) polymerase (PARP) inhibitors. Join Hope Rugo, MD, as she explores current treatment options in early-stage TNBC through case examples. This activity is intended for oncologists, pathologists and surgeons. The goal of this activity is for learners to be better able to improve clinicians’ ability to use immunotherapy and/or PARP inhibitors in patients with
Source: na.eventscloud.comCategories: General Medicine News, DermatologyTweet-
Join experts January 25 and learn about clinical data associated with newer therapies used to treat patients with #TNBC. Click here now: https://t.co/Va2yreWV9M https://t.co/GE55iAFN0x
-
-
Mashup Score: 0Home - 3 month(s) ago
The treatment of triple-negative breast cancer (TNBC) has evolved with the emergence of newer therapies such as immunotherapy and poly(ADP-ribose) polymerase (PARP) inhibitors. Join Hope Rugo, MD, as she explores current treatment options in early-stage TNBC through case examples. This activity is intended for oncologists, pathologists and surgeons. The goal of this activity is for learners to be better able to improve clinicians’ ability to use immunotherapy and/or PARP inhibitors in patients with
Source: na.eventscloud.comCategories: General Medicine News, DermatologyTweet-
Join experts January 25 and learn about clinical data associated with newer therapies used to treat patients with #TNBC. Click here now: https://t.co/Va2yreWV9M https://t.co/GE55iAFN0x
-
-
Mashup Score: 0Home - 3 month(s) ago
The treatment of triple-negative breast cancer (TNBC) has evolved with the emergence of newer therapies such as immunotherapy and poly(ADP-ribose) polymerase (PARP) inhibitors. Join Hope Rugo, MD, as she explores current treatment options in early-stage TNBC through case examples. This activity is intended for oncologists, pathologists and surgeons. The goal of this activity is for learners to be better able to improve clinicians’ ability to use immunotherapy and/or PARP inhibitors in patients with
Source: na.eventscloud.comCategories: General Medicine News, DermatologyTweet-
Join experts January 25 and learn about clinical data associated with newer therapies used to treat patients with #TNBC. Click here now: https://t.co/Va2yreWV9M https://t.co/GE55iAFN0x
-
-
Mashup Score: 1217-gene signature linked to remission after triple-negative breast cancer treatment - Mayo Clinic Comprehensive Cancer Center Blog - 5 month(s) ago
Associated with relapse-free survival, the genes may play a role in triggering inflammation to initiate an immune system response.
Source: cancerblog.mayoclinic.orgCategories: General Medicine News, General HCPsTweet-
RT @MayoCancerCare: 17-gene signature linked to remission after triple-negative breast cancer treatment https://t.co/pzZQc036mI #tnbc @Mayo…
-
-
Mashup Score: 3Therapy Progression in TNBC Leads to Important Second-Line Decision - 5 month(s) ago
In 2 separate, live virtual Case-Based Roundtable events, physicians from across the country discussed the treatment path from frontline therapy to second-line sacituzumab govitecan for patients with metastatic TNBC.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet-
As investigators continue to evaluate targeted therapies, some cancers present a separate challenge from most cases. This is where #TNBC sits in comparison with other subtypes of the disease. READ MORE: https://t.co/l4Al0LMTQ6
-
-
Mashup Score: 5HER2-Low Status Was Associated With Better Breast Cancer-Specific Survival in Early-Stage Triple-Negative Breast Cancer - 6 month(s) ago
HER2-low breast cancer as an independent biological subtype remains controversial. This study investigated the clinicopathological and prognostic characteristic
Source: academic.oup.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
HER2-low expression was associated with better survival vs. HER2-negative status in patients with #TNBC, especially in the high-risk groups. This indicates that HER2-low #breastcancer can be a potential independent biological subtype. #bcsm @dradityabardia https://t.co/wJ0UiINsjo https://t.co/D68qWeB6HE
-
-
Mashup Score: 0
Hope S. Rugo, MD, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, discusses what to do in patients with triple-negative breast cancer who have not achieved a pathological complete response (pCR), an area of unmet need in TNBC. Prof. Rugo discusses strategies currently under evaluation including trials altering treatment in the post-neoadjuvant setting, as well as improving outcomes using novel antibody-drug conjugates. This interview took place at the St. Gallen International Breast Cancer Consensus Meeting in Vienna, Austria. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
📣October is Breast Cancer Awareness Month 📅 Check out this interview from #BCC2023, where @hoperugo discusses options for patients with early-stage #TNBC who have not achieved a pCR: ➡️https://t.co/L6BfHqdP2V🎥 #BreastCancer #BCSM
-
-
Mashup Score: 0Breast Cancer Expert Describes Drug Shortages Impact in TNBC - 6 month(s) ago
Paolo Tarantino, MD, discusses how drug prices within the United States are affecting the treatment of breast cancer.
Source: www.cancernetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
While drug shortages have affected multiple areas of cancer care, Paolo Tarantino, MD, noted that patients in the breast cancer space who need carboplatin for curative intent, such as those with #TNBC, are being prioritized for treatment. @PTarantinoMD https://t.co/g2eMX1IHH6
-
đź“ŁWhat is the role of immune activation on the prognosis of early #TNBC if chemo is not given? We evaluated ~ 2,000 pts w eTNBC from 13 institutions around the globe to answer this. See our results published today in @JAMA_current https://t.co/N0fMyRWjP3 https://t.co/d21myFAop1